Pharmacotherapy after bariatric surgery in primary and specialized care with special attention to drug-related problems after discharge
Recruiting
- Conditions
- E66Obesity
- Registration Number
- DRKS00031211
- Lead Sponsor
- niversität Leipzig
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 100
Inclusion Criteria
Bariatric surgery during the study period
- Written informed consent to participate in the study
- Sufficient language skills to participate in the study
- Intake of at least on peroral drug (excl. postbariatric drugs such as proton pump inhibitors, ursodeoxycholic acid and postbariatric supplements)
- Discharge to home
Exclusion Criteria
- Non-fulfillment of inclusion criteria
- Rejection of participation by the patient or the treating physician of the study centre
- Discontinuation of all peroral medications after discharge
Study & Design
- Study Type
- observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Type and number of potential and manifest drug-related problems detected three weeks after surgery. Drug-related problems will be identified via medication analysis and patient and physician interviews.
- Secondary Outcome Measures
Name Time Method - Type and number of differences between discharge medication and patient- and physician-reported medication.<br>- Type and number of medication changes made by physicians after surgery (reported by the primary care physician).<br>- Number of medications prescribed that are consistent with the advice and recommendations for pharmacotherapy after bariatric surgery that can be found in the literature.<br>- Type, number, and success of solutions proposed by pharmacists and physicians involved in the project for the detected drug-related problems.